Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy

J Antimicrob Chemother. 1990 May;25(5):837-42. doi: 10.1093/jac/25.5.837.

Abstract

Six patients with newly diagnosed haematological malignancy were treated with ciprofloxacin 500 mg orally, as chemoprophylaxis during neutropenia. The mean serum ciprofloxacin concentrations, measured 1, 2, 3 and 4 h after dosage were reduced for up to ten days after the start of chemotherapy. The mean maximum serum concentration and AUC 0-4 h were reduced from 3.7 (95% confidence limits, 2.3-5.1) mg/l and 10.7 (6.2-15.2) mg/l.h pre-chemotherapy to 2.0 (1.4-2.6) mg/l and 5.7 (4.4-7.0) mg/l.h, 13 days after chemotherapy. Absorption of ciprofloxacin is reduced after cytotoxic chemotherapy, and this may have implications for the use of oral ciprofloxacin in this group of patients.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Ciprofloxacin / administration & dosage
  • Ciprofloxacin / pharmacokinetics*
  • Drug Interactions
  • Female
  • Humans
  • Intestinal Absorption / drug effects
  • Leukemia, Myeloid, Acute / drug therapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Male
  • Middle Aged

Substances

  • Ciprofloxacin